|
| Vasculitis (n = 31) | Lupus nephritis (n = 36) | Miscellaneous (n = 15) |
| Gender: Male/Female | 16/15 | 8/28 | 4/11 |
| Age: Median (IQR) | 65 (45 - 76) | 42 (29 - 55) | 60 (39.5 - 64.5) |
| Comorbidities |
|
|
|
| Hypertension | 18 | 25 | 7 |
| Cardiac Failure | 2 | 4 | 1 |
| Ischemic heart disease | 8 | 5 | 1 |
| Peripheral Vascular disease | 3 | 0 | 0 |
| Stroke | 1 | 4 | 3 |
| Malignancy | 4 | 2 | 3 |
| Diabetes Mellitus | 4 | 2 | 1 |
| Liver disease | 0 | 4 | 2 |
| Organ involvement |
|
|
|
| Cutaneous | 1 | 30 | 5 |
| Oral/nasal ulcers | 0 | 12 | 0 |
| ENT | 3 | 0 | 0 |
| Non scarring alopecia | 0 | 6 | 0 |
| Arthritis/Arthralgia | 4 | 29 | 3 |
| Serositis | 0 | 14 | 0 |
| Neurological | 4 | 7 | 3 |
| Hematological | 0 | 20 | 2 |
| Pulmonary | 8 | 3 | 3 |
| eGFR (ml/mt/1.73m2) Baseline Median (IQR) End of study Median (IQR) |
18 (9 - 41) 50 (24 - 68) |
67.5 (43.5 - 90) 81.5 (44 - 90) |
54 (29.5 - 64.5) 61.5 (40.5 - 85.5) |
| Urine protein/creatinine ratio Baseline Median (IQR) End of study Median (IQR) |
197 (87 - 420) 54 (15 - 147) |
85 (29 - 462) 29 (15 - 177) |
82 (23.5 - 183.5) 43.5 (20.5 - 146.5) |
| Number of patients on dialysis Baseline End of study |
6 1 |
2 2 |
1 0 |
| Number of renal transplants during course of study | 0 | 3 | 1 |
| Time since diagnosis (months) Median (IQR) Duration of follow up (months) Median (IQR) |
24 (15 - 51)
21 (14 - 45) |
52 (31 - 62)
45 (23 - 50) |
36 (22 - 46)
25 (14 - 41) |